Rezolute Consensus Price Target Increased by 18.70% to $9.28
The average one-year price target for Rezolute (NASDAQCM:RZLT) (DB:6HV1) has been revised to $9.28 / share. This is an increase of 18.70% from the prior estimate of $7.82 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $14.70 / share. The average price target represents an increase of 128.06% from the latest reported closing price of $4.07 / share as of October 1, 2026.
As of September 29, 2026, the median analyst target increased to $9.69 from a prior median of $6.12, representing an absolute median change of $3.57. The target range narrowed, with the current target range width at $8.64 compared to the prior width of $10.66, a decrease of -18.95%. The current gap between the mean and median targets stands at $0.41. Looking at the historical trajectory of the mean target, it was $9.28 on October 2, 2026, $7.82 on September 15, 2026, $7.82 on August 28, 2026, and $9.41 on August 4, 2026. This represents a -1.33% change since the 90-day baseline target of June 30, 2026. Over a twelve-month period, the observed high mean target was $16.09 on December 6, 2025, and the observed low mean target was $6.25 on December 21, 2025.
For context, Rezolute's stock price rose 3.30% over one week from a baseline close of $3.94 on September 24, 2026, but declined 9.56% over one month from a baseline close of $4.50 on September 1, 2026. In its latest earnings report on September 24, 2026, the company reported an actual EPS of -0.2 compared to an estimated EPS of -0.151, on actual revenue of $0.00 against an estimate of $0.00.
Recent analyst actions include Craig-Hallum upgrading the stock from Hold to Buy on September 29, 2026, Lake Street initiating coverage with a Buy rating on September 30, 2026, and HC Wainwright & Co. maintaining a Buy rating on September 25, 2026. As of September 1, 2026, the recommendation breakdown consisted of 6 strong buy, 7 buy, and 3 hold recommendations, totaling 16 recommendations (81.3% positive and 18.8% hold). This distribution was unchanged from the August 1, 2026 period.
Rezolute operates in the Biotechnology sub-industry. Within this sub-industry, 24 companies are covered, with 5 experiencing raised targets, 8 lowered, and 11 unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +81.91%.
The peer companies shown in the table below all had unchanged target revisions of 0.00%, though they exhibit positive implied changes ranging from +59.45% to +891.33%.
| Company | Target revision | Implied change |
|---|---|---|
| MBX Biosciences | 0.00% | +59.45% |
| Viking Therapeutics | 0.00% | +216.81% |
| Caribou Biosciences | 0.00% | +891.33% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.